<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00112463</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01037</org_study_id>
    <secondary_id>NCI-2012-01037</secondary_id>
    <secondary_id>CCCWFU 71103</secondary_id>
    <secondary_id>6319</secondary_id>
    <secondary_id>U10CA081851</secondary_id>
    <secondary_id>P30CA012197</secondary_id>
    <nct_id>NCT00112463</nct_id>
    <nct_alias>NCT01645683</nct_alias>
  </id_info>
  <brief_title>Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma</brief_title>
  <official_title>A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well depsipeptide (romidepsin) works in treating patients
      with metastatic or unresectable soft tissue sarcoma. Drugs used in chemotherapy, such as
      depsipeptide, work in different ways to stop the growth of tumor cells, either by killing the
      cells or by stopping them from dividing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To estimate the response rates of metastatic or unresectable soft tissue sarcomas to
      single-agent depsipeptide.

      II. To estimate the time to progression of metastatic or unresectable soft tissue sarcomas to
      single-agent depsipeptide.

      III. To evaluate the scope and extent of acute toxicities associated with single-agent
      depsipeptide when given to patients with soft tissue sarcomas.

      OUTLINE: This is a multicenter study.

      Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and
      15. Courses repeat every 28 days in the absence of disease progression or unacceptable
      toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond
      documentation of CR.

      After completion of study treatment, patients are followed up every 2 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 7, 2005</start_date>
  <completion_date type="Actual">October 23, 2008</completion_date>
  <primary_completion_date type="Actual">October 23, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Tumor Response (Complete and Partial)</measure>
    <time_frame>While on treatment - max of 16 months</time_frame>
    <description>Objective tumor response was evaluated using the criteria proposed by the Response Evaluation Criteria In Solid Tumors (RECIST) Committee (JNCI 92(3):205-216,2000). Changes in only the largest diameter (unidimensional measurement) of the target lesions are used. A sum of the longest diameter (LD) for all target lesions was calculated and reported as the baseline sum LD. The baseline sum LD was used as reference by which to characterize the objective tumor response. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum LD; Overall Response (OR) = CR + PR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>Until disease progression - max of 48 months</time_frame>
    <description>Progressive disease is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameters (LD) of target lesions, taking as reference the smallest sum LD recorded since treatment started, or a measurable increase in a non-target lesion, or the appearance of new lesions. Time to progression is the number of months from first treatment until the date of progression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity as Assessed Using the Expanded Common Toxicity Criteria Version 3</measure>
    <time_frame>During treatment (max of 16 months) and for 1 month following treatment</time_frame>
    <description>The outcome reported here is the number (%) of participants who experienced grade 3 or greater toxicity while on study.
A summary of the individual toxicities can be found in the AE/SAE results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Max of 98 months</time_frame>
    <description>Months from first treatment until death or the last date of contact</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Adult Alveolar Soft-part Sarcoma</condition>
  <condition>Adult Angiosarcoma</condition>
  <condition>Adult Epithelioid Sarcoma</condition>
  <condition>Adult Extraskeletal Chondrosarcoma</condition>
  <condition>Adult Extraskeletal Osteosarcoma</condition>
  <condition>Adult Fibrosarcoma</condition>
  <condition>Adult Leiomyosarcoma</condition>
  <condition>Adult Liposarcoma</condition>
  <condition>Adult Malignant Fibrous Histiocytoma</condition>
  <condition>Adult Malignant Hemangiopericytoma</condition>
  <condition>Adult Malignant Mesenchymoma</condition>
  <condition>Adult Neurofibrosarcoma</condition>
  <condition>Adult Rhabdomyosarcoma</condition>
  <condition>Adult Synovial Sarcoma</condition>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <condition>Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor</condition>
  <condition>Recurrent Adult Soft Tissue Sarcoma</condition>
  <condition>Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor</condition>
  <condition>Stage III Adult Soft Tissue Sarcoma</condition>
  <condition>Stage IV Adult Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (single-agent depsipeptide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>romidepsin</intervention_name>
    <description>DEP is administered at a dose of 13 mg/m2 as a 4-hour intravenous infusion in the outpatient setting.</description>
    <arm_group_label>Treatment (single-agent depsipeptide)</arm_group_label>
    <other_name>FK228</other_name>
    <other_name>FR901228</other_name>
    <other_name>Istodax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed soft tissue sarcoma (STS), including, but
             not limited to, the following histologies:

               -  Gastrointestinal stromal tumors (GIST)

                    -  Refractory to imatinib mesylate

               -  Desmoplastic small round cell tumors

               -  Clear cell sarcoma

               -  Extraskeletal osteosarcoma*

               -  Extraskeletal Ewing's sarcoma*

               -  Extraskeletal (myxoid) chondrosarcoma*

          -  Secondary STS (e.g., radiation-induced STS or neurofibrosarcoma due to
             neurofibromatosis) allowed

          -  Metastatic or unresectable disease

          -  No standard curative therapy exists

          -  Patients with GIST must have received and progressed on imatinib mesylate

          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by
             conventional techniques OR ≥ 10 mm by spiral CT scan

          -  No known brain metastases

          -  Performance status - Eastern Cooperative Oncology Group (ECOG) 0-2

          -  Performance status - Karnofsky 50-100%

          -  More than 3 months

          -  White blood cells (WBC) â¥ 3,000/mm^3

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) â¤ 2.5 times upper
             limit of normal (ULN)

          -  Bilirubin normal

          -  Creatinine &lt; 1.5 times ULN

          -  Creatinine clearance ≥ 60 mL/min

          -  QTc ≤ 480 msec

        Exclusion Criteria:

          -  No cardiac abnormalities (e.g., congenital long QT syndrome)

          -  No myocardial infarction within the past year

          -  No history of coronary artery disease (e.g., angina Canadian Class II-IV or positive
             stress imaging study)

          -  No cardiac ischemia (ST depression &gt;2 mm) by electrocardiogram (ECG)

          -  No New York Heart Association Class II-IV congestive heart failure

          -  Ejection fraction &gt; 50% by multi gated acquisition scan (MUGA) scan or echocardiogram

          -  No history of sustained ventricular tachycardia, ventricular fibrillation, Torsades de
             Pointes, or cardiac arrest unless controlled by an automatic implantable cardioverter
             defibrillator

          -  No hypertrophic or restrictive cardiomyopathy from prior treatment or other causes

          -  No significant left ventricular hypertrophy

          -  No uncontrolled hypertension (i.e., blood pressure ≥ 160/95 mm Hg)

          -  No cardiac arrhythmia requiring anti-arrhythmic medication

               -  Beta blocker or calcium channel blocker allowed

               -  Patients on digitalis that cannot be discontinued not allowed

          -  No Mobitz II second degree block without a pacemaker (first degree or Mobitz I second
             degree block, bradyarrhythmias, or sick sinus syndrome require Holter monitoring and
             evaluation by cardiology)

          -  No uncontrolled dysrhythmia

          -  No poorly controlled angina

          -  No other cardiac disease

          -  No history of allergic reaction attributed to compounds of similar chemical or
             biological composition to FR901228

          -  No ongoing or active infection

          -  No iatrogenic immune deficiency or immune deficiency secondary to an underlying
             disorder

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Potassium ≥ 4.0 mmol/L

          -  Magnesium ≥ 2.0 mg/dL

          -  No other uncontrolled illness

          -  No psychiatric illness or social situation that would preclude study compliance

          -  No concurrent anticancer biologic agents

          -  No more than 1 prior chemotherapy regimen for sarcoma

               -  Adjuvant chemotherapy preceding disease relapse is considered 1 prior
                  chemotherapy regimen

               -  Patients with GIST may have received up to 3 prior chemotherapy regimens
                  comprising imatinib mesylate and/or sunitinib malate provided no other
                  chemotherapy agents were used

          -  No prior FR901228 (depsipeptide)

          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

          -  No prior cumulative doxorubicin dose &gt; 500 mg/m^2

          -  No other concurrent anticancer chemotherapy

          -  At least 4 weeks since prior radiotherapy

          -  No concurrent anticancer radiotherapy

          -  At least 4 weeks since prior surgery

          -  No prior organ transplantation

          -  Recovered from all prior therapy

          -  No concurrent medications that cause QTc prolongation

          -  No concurrent combination highly active anti-retroviral therapy for HIV-positive
             patients

          -  No other concurrent drugs known to have histone deacetylase inhibitor activity (e.g.,
             sodium valproate)

          -  No other concurrent investigational agents

          -  No other concurrent anticancer agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Savage</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2005</study_first_submitted>
  <study_first_submitted_qc>June 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2005</study_first_posted>
  <results_first_submitted>April 4, 2017</results_first_submitted>
  <results_first_submitted_qc>April 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 12, 2017</results_first_posted>
  <last_update_submitted>May 18, 2017</last_update_submitted>
  <last_update_submitted_qc>May 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Leiomyosarcoma</mesh_term>
    <mesh_term>Liposarcoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
    <mesh_term>Chondrosarcoma</mesh_term>
    <mesh_term>Sarcoma, Synovial</mesh_term>
    <mesh_term>Hemangiosarcoma</mesh_term>
    <mesh_term>Fibrosarcoma</mesh_term>
    <mesh_term>Hemangiopericytoma</mesh_term>
    <mesh_term>Histiocytoma</mesh_term>
    <mesh_term>Sarcoma, Alveolar Soft Part</mesh_term>
    <mesh_term>Histiocytoma, Benign Fibrous</mesh_term>
    <mesh_term>Histiocytoma, Malignant Fibrous</mesh_term>
    <mesh_term>Mesenchymoma</mesh_term>
    <mesh_term>Neurofibrosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Romidepsin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Single-agent Depsipeptide)</title>
          <description>Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Second Primary</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Never started treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All registered participants</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Single-agent Depsipeptide)</title>
          <description>Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="19" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Tumor Response (Complete and Partial)</title>
        <description>Objective tumor response was evaluated using the criteria proposed by the Response Evaluation Criteria In Solid Tumors (RECIST) Committee (JNCI 92(3):205-216,2000). Changes in only the largest diameter (unidimensional measurement) of the target lesions are used. A sum of the longest diameter (LD) for all target lesions was calculated and reported as the baseline sum LD. The baseline sum LD was used as reference by which to characterize the objective tumor response. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum LD; Overall Response (OR) = CR + PR</description>
        <time_frame>While on treatment - max of 16 months</time_frame>
        <population>Participants who were evaluable for response</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Single-agent Depsipeptide)</title>
            <description>Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Tumor Response (Complete and Partial)</title>
          <description>Objective tumor response was evaluated using the criteria proposed by the Response Evaluation Criteria In Solid Tumors (RECIST) Committee (JNCI 92(3):205-216,2000). Changes in only the largest diameter (unidimensional measurement) of the target lesions are used. A sum of the longest diameter (LD) for all target lesions was calculated and reported as the baseline sum LD. The baseline sum LD was used as reference by which to characterize the objective tumor response. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum LD; Overall Response (OR) = CR + PR</description>
          <population>Participants who were evaluable for response</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Progression</title>
        <description>Progressive disease is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameters (LD) of target lesions, taking as reference the smallest sum LD recorded since treatment started, or a measurable increase in a non-target lesion, or the appearance of new lesions. Time to progression is the number of months from first treatment until the date of progression.</description>
        <time_frame>Until disease progression - max of 48 months</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Single-agent Depsipeptide)</title>
            <description>Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Progressive disease is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameters (LD) of target lesions, taking as reference the smallest sum LD recorded since treatment started, or a measurable increase in a non-target lesion, or the appearance of new lesions. Time to progression is the number of months from first treatment until the date of progression.</description>
          <population>All treated participants</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.7" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Toxicity as Assessed Using the Expanded Common Toxicity Criteria Version 3</title>
        <description>The outcome reported here is the number (%) of participants who experienced grade 3 or greater toxicity while on study.
A summary of the individual toxicities can be found in the AE/SAE results.</description>
        <time_frame>During treatment (max of 16 months) and for 1 month following treatment</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Single-agent Depsipeptide)</title>
            <description>Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.
romidepsin: DEP is administered at a dose of 13 mg/m2 as a 4-hour intravenous infusion in the outpatient setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity as Assessed Using the Expanded Common Toxicity Criteria Version 3</title>
          <description>The outcome reported here is the number (%) of participants who experienced grade 3 or greater toxicity while on study.
A summary of the individual toxicities can be found in the AE/SAE results.</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival</title>
        <description>Months from first treatment until death or the last date of contact</description>
        <time_frame>Max of 98 months</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Single-agent Depsipeptide)</title>
            <description>Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>Months from first treatment until death or the last date of contact</description>
          <population>All treated participants</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="7.6" upper_limit="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During treatment (max of 16 months) and for 1 month following treatment</time_frame>
      <desc>Toxicities were evaluated weekly while the participant was on treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Single-agent Depsipeptide)</title>
          <description>Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulation - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia - Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cardiac Dysrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cardiac General - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>GI - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Malise/Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Metabolic - Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulation - Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="84" subjects_affected="11" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Caridac General - Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes/flushes</sub_title>
                <counts group_id="E1" events="19" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="5" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="82" subjects_affected="19" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Constitutional Symptioms - Other</sub_title>
                <counts group_id="E1" events="51" subjects_affected="13" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dyspepsia/Heartburn</sub_title>
                <counts group_id="E1" events="20" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>GI - Other</sub_title>
                <counts group_id="E1" events="65" subjects_affected="25" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="150" subjects_affected="26" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="42" subjects_affected="15" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>AGC/ANC</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever in the absence of neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>WBC</sub_title>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="55" subjects_affected="9" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Malise/Fatigue</sub_title>
                <counts group_id="E1" events="198" subjects_affected="32" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Metabolic - Other</sub_title>
                <counts group_id="E1" events="21" subjects_affected="9" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Weight Gain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" events="18" subjects_affected="11" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other</sub_title>
                <counts group_id="E1" events="23" subjects_affected="11" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="16" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Neurologic - Other</sub_title>
                <counts group_id="E1" events="59" subjects_affected="14" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" events="123" subjects_affected="22" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pain: Abdomen NOS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pain: Back</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pain: Extremity-limb</sub_title>
                <counts group_id="E1" events="15" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pain: Head/Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pain: NOS</sub_title>
                <counts group_id="E1" events="22" subjects_affected="7" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Taste Alteration</sub_title>
                <counts group_id="E1" events="49" subjects_affected="7" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary - Other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea/SOB</sub_title>
                <counts group_id="E1" events="26" subjects_affected="14" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pulmonary Other</sub_title>
                <counts group_id="E1" events="18" subjects_affected="7" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Doug Case</name_or_title>
      <organization>Wake Forest School of Medicine</organization>
      <phone>336-716-1048</phone>
      <email>dcase@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

